
Treatments aimed at certain mutations have proliferated and moved upstream to earlier-stage lung cancers. But there are many questions about insurance coverage and which tests to use to identify the biomarkers that help guide treatment.

Treatments aimed at certain mutations have proliferated and moved upstream to earlier-stage lung cancers. But there are many questions about insurance coverage and which tests to use to identify the biomarkers that help guide treatment.

Although smoking is the predominate risk factor for lung cancer, about 1 in 5 cases cases are believed to be linked to genetic factors.

“Lung cancer screening is a great example of the problem,” says the former chief medical and scientific officer for the American Cancer Society in this third of four-part video series.

Lowering the age and smoking history standards would result in substantially more Blacks and women being eligible for screening.